Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Acelyrin raises $250M in Series B funding round

By Brian Buntz | November 16, 2021

AcelyrinFounded in late 2020, Acelyrin has closed a $250 million Series B financing led by AyurMaya, an affiliated fund of Matrix Capital Management, Surveyor Capital and Westlake Village BioPartners.

Other investors joining the funding round included Cowen Healthcare Investments, Decheng Capital, Marshall Wace, OrbiMed, RTW Investments, LP, Samsara BioCapital, Tybourne Capital Management and venBio Partners.

Acelyrin announced its Series A funding round in December 2020 from Westlake Village BioPartners. The company did not share the size of the fundraising round.

In related news, Los Angeles–based Acelyrin announced that Affibody AB (Stockholm, Sweden) had licensed izokibep, a late-stage IL-17A inhibitor for treating inflammatory diseases.

Izokibep is an interleukin-17A (IL-17A) inhibitor that Acelyrin believes has potential in treating several autoimmune diseases.

Acelyrin is now enrolling patients in an izokibep pivotal trial for treating uveitis, a type of inflammation within the eye. It is also enrolling for a Phase 2b trial focused on axial spondyloarthritis. The company also intends to launch a Phase 2b trial for hidradenitis suppurativa (HS), a chronic inflammatory disease involving the exocrine sweat glands.

Acelyrin plans on using the latest funding round for licensing, continuing the development of izokibep and acquiring additional programs.

The company is eyeing a potential intial public offering in 2022.


Filed Under: clinical trials, Drug Discovery
Tagged With: Acelyrin, AyurMaya, interleukin-17A, izokibep, Matrix Capital Management, Surveyor Capital, Westlake Village BioPartners
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Diversity
Making diversity in clinical research more than a talking point
psychedelic medicine discussed at SXSW
5 headwinds and 5 tailwinds for psychedelic medicine
lab microscope
Accelerating R&D with FAIR data
Kallyope
Kallyope’s focus on the gut-brain axis yields a diverse portfolio

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Medtech100 Index
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50